Arvinas, Inc. (ARVN)
$9.34-0.32%Close
BUYRECOVERY · day 44
Key stats
Short interest · FINRA settlement 2026-07-31
- Market cap
- $603M
- Avg volume
- 828.8K
- Beta
- 1.74
- P/E (TTM)
- 49.16
- Short % float
- 7.15%
- Days to cover
- 7.0
- SI change
- +0.4%
- 1W
- +1.52%
- 1M
- +16.31%
- 3M
- +2.75%
- YTD
- -18.57%
- vs SPY 1W
- +2.71%
- vs SPY 1M
- +12.99%
- vs SPY 3M
- +0.36%
- vs SPY YTD
- -30.32%
Sector peers
Same-sector names ranked by LOPJLB quality proximity · Healthcare
- NKTXBUYNkarta, Inc.RECOVERYQ -7$2.59-2.63%
- SBFMBUYSunshine Biopharma, Inc.CRISISQ -16$1.16+0.00%
- NCNABUYNuCana plcRECOVERYQ -21$1.47-3.29%
- SHPHBUYShuttle Pharmaceuticals Holdings, Inc.CRISISQ -35$3.52-6.38%
- ALDXSELLAldeyra Therapeutics, Inc.RECOVERYQ -4$1.52+0.00%
- APGEBUYApogee Therapeutics, Inc.BULLQ 60$134.79+0.03%
- ATTOFLATAttovia Therapeutics, Inc.Q 18$20.62-0.87%
- BMEABUYBiomea Fusion, Inc.RECOVERYQ -5$1.59+16.06%
- CGTXBUYCognition Therapeutics, Inc.RECOVERYQ -11$0.98-2.00%
- KARDSELLKardigan, Inc.Q 18$20.64-1.81%
- NMRASELLNeumora Therapeutics, Inc. Common StockRECOVERYQ -28$1.53-6.13%
- SGPBUYSpyGlass Pharma, Inc. Common StockQ 9$26.26-0.94%
Industry peers
FMP comparable companies · ranked by market cap
- ERASSELLErasca, Inc.$5.9BRECOVERYQ 6$17.08-0.17%
- IOVABUYIovance Biotherapeutics, Inc.$4.0BRECOVERYQ 7$8.99-2.77%
- DAWNDay One Biopharmaceuticals, Inc.$2.2B$21.53
- AVBPSELLArriVent BioPharma, Inc.$1.4BRECOVERYQ 21$29.18-2.95%
- MGTXBUYMeiraGTx Holdings plc$1.3BBULLQ 9$14.54+3.42%
- REPLBUYReplimune Group, Inc.$1.2BRECOVERYQ 15$14.05-0.41%
- GERNBUYGeron Corporation$994MRECOVERYQ 11$1.55+0.00%
- ATXSAstria Therapeutics, Inc.$718M$12.58
- VALNBUYValneva SE$647MRECOVERYQ 1$6.82-3.02%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 18
- VALUE
- 3
- GROWTH
- 57
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC1.1%
REV YoY-
ROE1.9%
EPS YoY-
ROA1.4%
GROSS96
OP-4
NET3
[VALUATION]
P/E TTM49.16
P/E FWD-
SECTOR PE22.66
INDUSTRY PE17.07
P/B1.08
P/FCF-
EV/EBITDA178.04
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E1.42
ALTMAN Z-
CURR RATIO7.91
ND/EBITDA-
BETA1.74
